Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169637
Status:
COMPLETED
Last Update Posted:
2008-10-31
First Post:
2005-09-12
Brief Title:
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone rhGH in the Treatment of Children With Short Bowel Syndrome
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone rhGH in the Treatment of Children With Short Bowel Syndrome
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized controlled parallel group open label versus no treatment trial which evaluate the efficacy of rhGH on weaning off parenteral nutrition in children with short bowel syndromeThe total follow-up is 14 months 4 months for each group after randomization At the end of the first four months the treated group will be followed within 6 months the untreated group will receive compassionately rhGH for 4 months and followed-up for 6 months after the end of the treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None